ProShares Trust has announced the removal of its securities from listing and registration on NYSE Arca, effective November 9, 2026. This significant decision follows the suspension of trading that occurred on October 13, 2026. The removal highlights the evolving landscape within the investment sector and raises questions about the future of the affected securities.
ProShares Trust, an investment entity based in Bethesda, Maryland, is known for its diverse range of exchange-traded funds (ETFs). The company has filed several forms with the SEC, including recent filings on October 22 and 19, 2026, indicating ongoing activity within its operations. The firm’s securities include various ETFs, such as the ProShares MSCI Transformational Changes ETF and the ProShares Metaverse ETF.
The filing reveals that NYSE Arca has notified the SEC of its intention to remove the entire class of ProShares securities from listing. According to the filing, this decision is made under Rule 12d2-2(a)(3), which states that the securities have come to represent other securities by operation of law or otherwise. This means that the rights associated with the securities have changed, and they will now represent an immediate cash payment instead.
This change may affect various stakeholders, including investors and competitors within the investment industry. The suspension of trading and subsequent removal from listing could lead to a reevaluation of investment strategies among other firms and ETFs. As ProShares navigates this transition, it may prompt other companies to reassess their positions in the market.
The filing does not specify what actions ProShares will take next, leaving the future of its investment offerings uncertain. Investors and industry analysts will be watching closely for further developments from the company.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






